| Ervebo (recombinant vesicular stomatitis virus (VSV) expressing the envelope glycoprotein of Ebola Virus Zaire) / Merck (MSD) |
| Not yet recruiting | 4 | 40 | RoW | rVSVDG-ZEBOV-GP Ebola Virus Vaccine (ERVEBO) | Tulane University, Kenema Government Hospital, Merck Sharp & Dohme LLC | Ebola Virus Disease | 07/25 | 08/25 | | |
NCT06587503: Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses |
|
|
| Not yet recruiting | 4 | 72 | NA | BioNTech - Pfizer COVID-19 vaccine, Cominarty, 1mL saline solution, rVSV∆G-ZEBOV-GP, Ervebo | University of Birmingham, Project San Francisco, Rwanda Biomedical Centre, Merck Sharp & Dohme LLC | Ebola Virus Disease, COVID-19 | 12/24 | 05/25 | | |
EBO-BOOST, NCT06126822: Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination With the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC |
|
|
| Not yet recruiting | 3 | 624 | RoW | Zabdeno® booster, Ervebo® booster | Institute of Tropical Medicine, Belgium, Institut National pour la Recherche Biomedicale (INRB) | Ebola Virus Disease | 10/25 | 10/26 | | |
PREPARE, NCT05959421: Immunity Induced by VSV-EBOV and Assessment of a Booster Dose in Individuals at Potential Occupational Risk for Exposure |
|
|
| Not yet recruiting | 3 | 70 | Europe | ERVEBO® (rVSV∆G-ZEBOV-GP) | Universitätsklinikum Hamburg-Eppendorf, Bernhard Nocht Institute for Tropical Medicine, Goethe University, German Federal Ministry of Education and Research, Monipol Deutschland GmbH | Ebola Vaccine | 03/26 | 02/27 | | |
| Not yet recruiting | 2a | 250 | RoW | ansuvimab, mab114, Ervebo, VSV-ZEBOV | ANRS, Emerging Infectious Diseases | Ebola Virus Disease | 04/22 | 04/22 | | |
NCT05202288: Pilot Study Evaluating the Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers |
|
|
| Not yet recruiting | 2a | 135 | RoW | Ervebo, r-VSV-ZEBOV vaccine, Inmazeb, REGN-E3B | ANRS, Emerging Infectious Diseases, Alliance for International Medical Action, University of Bordeaux, Institut National de la Santé Et de la Recherche Médicale, France, Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire, Agence Nationale de Sécurité Sanitaire de Guinée (ANSS), Clinical and Operational Research Alliance (CORAL), Méthodologie et Evaluation pour la Recherche clinique et Epidémiologique sur le VIH en Afrique (MEREVA) | Ebola Virus Disease | 03/23 | 03/23 | | |
| Completed | 2 | 4789 | RoW | Ad26.ZEBOV, rHAd26, MVA-BN-Filo, MVA, MVA-mBN226B, rVSVΔG-ZEBOV-GP, rVSV, V920, Placebo, rVSV boost | National Institute of Allergy and Infectious Diseases (NIAID), Partnership for Research on Ebola Virus in Liberia (PREVAIL), Institut National de la Santé Et de la Recherche Médicale, France, London School of Hygiene and Tropical Medicine, European and Developing Countries Clinical Trials Partnership (EDCTP) | Ebola Virus Disease | 12/19 | 12/23 | | |
| Active, not recruiting | 2 | 250 | Canada | V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine, Saline | Cecile Tremblay, Merck Sharp & Dohme LLC, International Development Research Centre, Canada, Dalhousie University, Université de Montréal, Coalition for Epidemic Preparedness Innovations | Ebola | 10/24 | 02/25 | | |
NCT02788227: Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV[Delta]G-ZEBOV-GP) for Pre-Exposure Prophylaxis (PREP) in People at Potential Occupational Risk for Ebola Virus Exposure |
|
|
| Enrolling by invitation | 2 | 200 | US | rVSV-Zebov GP vaccine | National Institute of Allergy and Infectious Diseases (NIAID) | Healthy Volunteers | 12/25 | 12/25 | | |
| Recruiting | 2 | 30 | US | Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP), Ervebo | Emory University, Washington University School of Medicine, Merck Sharp & Dohme LLC | Ebola Virus Disease | 12/26 | 12/26 | | |
EBOLAPED, NCT05130398: Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon |
|
|
| Completed | 1/2 | 120 | RoW | rVSVΔG-ZEBOV-GP, V920, Fibre and equilibrate breakfast and lunch, Active detection and treatment of pathogens, Fibre and equilibrate breakfast and lunch plus Active detection and treatment of pathogens, Chikenpox or Varicella vaccine (VARILRIX), Placebo | Centre de Recherche Médicale de Lambaréné, Merck Sharp & Dohme LLC | Ebola Virus Disease | 09/21 | 08/22 | | |
NCT02257840: Safety and Immunogenicity of Prime-Boost VSV Ebola Vaccine in Healthy Adults |
|
|
| Recruiting | 1 | 120 | US | Placebo, BPSC1001 | National Institute of Allergy and Infectious Diseases (NIAID) | Ebola Viruses | 10/15 | 10/15 | | |
EBOSURV, NCT05313139: Surveillance of Vaccine-induced Immunity Against Ebola in Previously Vaccinated Health Care Workers |
|
|
| Recruiting | N/A | 245 | RoW | | Institute of Tropical Medicine, Belgium | Immune Response | 08/22 | 12/22 | | |
